<DOC>
	<DOCNO>NCT01903083</DOCNO>
	<brief_summary>The goal study evaluate safety combination treatment include chemotherapy , radiation therapy , immunotherapy patient pancreatic cancer .</brief_summary>
	<brief_title>Chemoimmunotherapy Radiation Pancreatic Cancer</brief_title>
	<detailed_description>This study borderline resectable advanced pancreatic cancer patient . Patients receive chemotherapy gemcitabine immunotherapy daily tadalafil first 21 day treatment . On study day 22 , patient receive first three plan dos radiation therapy continue daily tadalafil . Patients evaluated determine candidate pancreaticoduodenectomy . Patients candidate continue daily tadalafil receive gemcitabine chemotherapy . Patients surgery resume daily tadalafil gemcitabine chemotherapy follow recovery surgery . Patients receive four cycle gemcitabine .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Pancreatic adenocarcinoma Locally advance unresectable disease , borderline resectable disease ECOG ( Eastern Cooperative Oncology Group ) Performance Status 0 1 Ability provide consent comply study protocol Women childbearing potential must negative pregnancy test avoid pregnancy study Age &lt; 18 History malignancy previous 2 year except carcinoma situ cervix bladder , nonmelanoma skin cancer Previous chemotherapy radiation therapy pancreatic cancer previous radiation target field Clinically active autoimmune disease active infection History heart attack within 90 day stroke within 6 month , hypertension require change blood pressure medication last 4 week , hypotension , uncontrolled arrhythmia , heart failure ( NYHA &gt; = Class 2 last 6 month ) , unstable angina , angina sexual activity Use nitrate nitroglycerin History hereditary degenerative retinal disorder include retinitis pigmentosa Chronic systemic corticosteroid use supraphysiologic dos Use recreational drug call 'poppers ' like amyl nitrite butyl nitrite Blood test result ( neutrophils &lt; 1000 /uL ( microliter ) ; hemoglobin &lt; 9 gm /dL ; platelet count &lt; 1000 cell / uL ; significant coagulopathy ; significant liver renal dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Pancreas</keyword>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Radiation</keyword>
	<keyword>Surgery</keyword>
	<keyword>Pancreaticoduodenectomy</keyword>
</DOC>